



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)


[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## MCC950 sodium

## Chemical Properties

CAS No. :	256373-96-3
Formula:	C <sub>20</sub> H <sub>23</sub> N <sub>2</sub> O <sub>5</sub> S <sub>1</sub> Na
Molecular Weight:	426.46
Appearance:	no data available
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year



## Biological Description

Description	MCC950 sodium (CP-456773 sodium) is a potent and selective inhibitor of the inflammatory vesicle NLRP3 (IC <sub>50</sub> =7.5 nM in BMDMs; IC <sub>50</sub> =8.1 nM in HMDMs). MCC950 sodium has no effect on other inflammatory vesicles such as AIM2, NLRC4 or NLRP1.
Targets(IC <sub>50</sub> )	NOD-like Receptor (NLR),NOD
In vitro	<p><b>METHODS:</b> Mouse bone marrow-derived macrophages BMDM were stimulated with LPS (10 ng/mL) for 3 h, stimulated with MCC950 sodium (1-1000 nM) for 30 min, and then treated with ATP (5 mM) for 1 h. Levels of IL-1<math>\beta</math> and TNF-<math>\alpha</math> were measured by ELISA.</p> <p><b>RESULTS:</b> MCC950-treated cells dose-dependently inhibited the release of IL-1<math>\beta</math> in BMDM, and LPS-dependent TNF-<math>\alpha</math> secretion was not impaired by MCC950. [1] MCC950 was used in the treatment of BMDM cells.</p> <p><b>METHODS:</b> Mouse macrophages, human coronary artery endothelial cells and smooth muscle cells were treated with MCC950 sodium (0.02-20 <math>\mu</math>M) for 3 days, and cell viability was measured by Alamar Blue assay.</p> <p><b>RESULTS:</b> MCC950 sodium had no toxic effect on the three cells. [2]</p>
In vivo	<p><b>METHODS:</b> To detect anti-NLRP3 activity in vivo, MCC950 sodium (20 mg/kg) was injected intraperitoneally into a mouse model of the human CAPS disease MWS once daily for four weeks.</p> <p><b>RESULTS:</b> MCC950 rescued the CAPS mouse model and inhibited NLRP3 in human MWS cells. [1]</p> <p><b>METHODS:</b> To investigate the pharmacological effects on experimental spinal cord injury models in vivo and neuronal injury in vitro, MCC950 sodium (10-50 mg/kg) was intraperitoneally injected into C57BL/6 mice with spinal cord injury (SCI).</p> <p><b>RESULTS:</b> MCC950 improved grip strength, hindlimb movement, spinal cord edema, and pathological damage in SCI mice. It exerted this effect by blocking NLRP3 inflammatory vesicle assembly and the release of the pro-inflammatory cytokines TNF-<math>\alpha</math>, IL-1<math>\beta</math>, and IL-18. [3]</p>
Kinase Assay	kinase activity assays: All assays are carried out in 384-well white microtiter plates. Compounds are 4-fold serially diluted in 8 steps, starting from 10 $\mu$ M. The reaction mixture consisted of 25 $\mu$ L assay buffer (50 mM HEPES pH 7.5, 10 mM MgCl <sub>2</sub> , 5 mM MnCl <sub>2</sub> , 1 mM DTT, 0.1 mM Na <sub>3</sub> VO <sub>4</sub> , 5 mM $\beta$ -glycerol phosphate). For FLT3 assays, the reaction contains 2.0 $\mu$ g/mL FLT3 enzyme, 5 $\mu$ M of poly(Glu,Tyr) substrate and 4 $\mu$ M of ATP. For JAK1 assays, the reaction contains 2.5 $\mu$ g/mL of JAK1 enzyme, 10 $\mu$ M of poly(Glu,Ala,Tyr) substrate and 1.0 $\mu$ M of ATP. For JAK2 assays, the reaction contained 0.35

$\mu\text{g/mL}$  of JAK2 enzyme,  $10\ \mu\text{M}$  of poly (Glu,Ala,Tyr) substrate and  $0.15\ \mu\text{M}$  of ATP. For JAK3 assays, the reaction contained  $3.5\ \mu\text{g/mL}$  of JAK3 enzyme,  $10\ \mu\text{M}$  of poly (Glu,Ala,Tyr) substrate and  $6.0\ \mu\text{M}$  of ATP. For TYK2 assays, the reaction contained  $2.5\ \mu\text{g/mL}$  of TYK2 enzyme,  $10\ \mu\text{M}$  of poly (Glu,Ala,Tyr) substrate and  $0.15\ \mu\text{M}$  of ATP. The reaction is incubated at room temperature for 2 h prior to addition of  $13\ \mu\text{L}$  PKLight<sup>®</sup> detection reagent. After 10 min incubation luminescent signals are read on a multi-label plate reader.

Cell Research	MCC950 is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. BMDM are seeded at $5 \times 10^5/\text{mL}$ or $1 \times 10^6/\text{mL}$ , HMDM at $5 \times 10^5/\text{mL}$ and PBMC at $2 \times 10^6/\text{mL}$ or $5 \times 10^6/\text{mL}$ in 96 well plates. The following day the overnight medium is replaced and cells are stimulated with $10\ \text{ng/mL}$ LPS from Escherichia coli serotype EH100 (ra) TLRgrad for 3 h. Medium is removed and replaced with serum free medium (SFM) containing DMSO (1:1,000), MCC950 (0.001- $10\ \mu\text{M}$ ), glyburide ( $200\ \mu\text{M}$ ), Parthenolide ( $10\ \mu\text{M}$ ) or Bayer cysteinyl leukotriene receptor antagonist 1-(5-carboxy-2-{3-[4-(3-cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic acid ( $40\ \mu\text{M}$ ) for 30 min. Cells are then stimulated with inflammasome activators: $5\ \text{mM}$ adenosine 5'-triphosphate disodium salt hydrate (ATP) (1 h), $1\ \mu\text{g/mL}$ Poly (deoxyadenylic-thymidylic) acid sodium salt (Poly dA:dT) transfected with Lipofectamine 200 (3-4 h), $200\ \mu\text{g/mL}$ MSU (overnight) and $10\ \mu\text{M}$ nigericin (1 h) or S. typhimurium UK-1 strain. Cells are also stimulated with $25\ \mu\text{g/mL}$ Polyadenylic-polyuridylic acid (4 h). For non-canonical inflammasome activation cells are primed with $100\ \text{ng/mL}$ Pam3CSK4 for 4 h, medium is removed and replaced with SFM containing DMSO or MCC950 and $2\ \mu\text{g/mL}$ LPS is transfected using 0.25% FuGENE for 16 h. Supernatants are removed and analysed using ELISA kits. LDH release is measured using the CytoTox96 non-radioactive cytotoxicity assay[1].
Animal Research	C57BL/6 mice were injected intraperitoneally with $50\ \text{mg/kg}$ MCC950.

### Solubility Information

Solubility	H <sub>2</sub> O: $42.7\ \text{mg/mL}$ ( $100\ \text{mM}$ ), DMSO: $55\ \text{mg/mL}$ ( $128.97\ \text{mM}$ ), ( $< 1\ \text{mg/mL}$ refers to the product slightly soluble or insoluble)
------------	---

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3449 mL	11.7244 mL	23.4489 mL
5 mM	0.469 mL	2.3449 mL	4.6898 mL
10 mM	0.2345 mL	1.1724 mL	2.3449 mL
50 mM	0.0469 mL	0.2345 mL	0.469 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

### Reference

Luo F, Lin J. Effects of Propofol Anesthesia on Pyroptosis and the Nod-Like Receptor Protein 3/Caspase-1 Pathway in the Neonatal Rat Hippocampus. Indian Journal of Pharmaceutical Sciences. 2023, 85(2): 338-343.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481